Fit women with locally advanced breast cancer (LABC) are treated with a combination of chemotherapy, radiation treatment and surgery. There is no set order for the radiation treatment or surgery, and no agreement about the type of surgery. Women are not always given the chance to have breast conservation surgery (BCS) because there is not enough evidence internationally that provesthis is safe, even though it has been offered to some women in some Cancer Centres around the world for the last 10 years with very good results.
There is no evidence that having BCS reduces the chance of being cured of LABC, compared to having a mastectomy. Having a mammogram and ultrasound at diagnosis and at the end of chemotherapy is normal practice. Some women have a mammogram and/or ultrasound at some time during chemotherapy, but not all. Some women have a breast Magnetic Resonance Imaging (MRI) scan before, during or after chemotherapy, but not all women. PET-CT scans are done occasionally.
The purpose of this study is to;
Investigate whether women with LABC can have breast conservation surgery (BCS) instead of mastectomy, with a low chance of cancer coming back in the breast.
Work out if breast Magnetic Resonance Imaging (MRI) and PET-CT are better ways of seeing how breast cancer responds to chemotherapy or hormone therapy compared to mammogram, ultrasound and examination by doctors.
The study will investigate whether the quality of life is better for women with LABC who undergo BCS rather than mastectomy and why some women decide (and doctors recommend) to have one form of surgery or the other (BCS or mastectomy), or have their type of chemotherapy changed.
Closing Date of Accrual
A/Prof Verity Ahern, Westmead Hospital, NSW
Clinical Trial Registration
The journey to becoming the 200th participant for the
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292